Delgocitinib: 12 agencies, 2020–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 6.4 years, from 22 Apr 2020 at CHUIKYO (Japan) to 3 Sep 2026 at HIRA (South Korea).
CIPM (Spain) changed its position: not recommended on 16 Jul 2025, recommended by 22 Oct 2025, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 12 of 14 records date from 2023 or later.
4 distinct indication wordings are recorded for delgocitinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
CHUIKYO (Japan) was first to assess delgocitinib, on 22 Apr 2020; HIRA (South Korea) did not open a file until 3 Sep 2026 — a wide spread of 6.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 7 of 13 dated records fall in 2025 alone.
2 of the 12 agencies here assessed delgocitinib more than once, PBAC (Australia) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
delgocitinib has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for delgocitinib reads 8 recommended, 2 not recommended, 1 restricted and 1 appraised, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 20 Aug 2026 | Advies - vergoed delgocitinib (Anzupgo®) voor de behandeling van chronisch handeczeem | reimbursed | source |
| AOTMIT (Poland) | 4 Aug 2026 | Anzupgo reimbursement recommendation | recommended conditionally | source |
| PBAC (Australia) | 2026 | Chronic hand eczema (CHE) | Not Recommended | source |
| TLV (Sweden) | 15 Jun 2026 | Anzupgo ingår i högkostnadsskyddet | general subsidy | source |
| SMC (Scotland) | 8 Dec 2025 | Treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids (TCS) are inadequate or inappropriate. | accepted | source |
9 further decisions for delgocitinib, across 8 agencies, are not shown here. They include the most recent record on file, 3 Sep 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- dupilumab — same ATC class D11A — Other dermatologicals
- abrocitinib — same ATC class D11A — Other dermatologicals
- nemolizumab — same ATC class D11A — Other dermatologicals
- lebrikizumab — same ATC class D11A — Other dermatologicals
- diclofenac — same ATC class D11A — Other dermatologicals
- ivermectin — same ATC class D11A — Other dermatologicals
Coverage: 14 decisions for delgocitinib from 12 agencies, 2020 to 2026. Data to 7 Sep 2026. ATC class D11A — Other dermatologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.